| Document |
Document Title |
|
WO/2018/167800A1 |
The present invention relates to fused bicyclic compounds that are inhibitors of GPR91, their stereoisomers, tautomers, prodrugs, polymorphs, solvates, pharmaceutically acceptable salts, and pharmaceutical compositions containing them. T...
|
|
WO/2018/165615A1 |
The invention is directed to roles for PARP-1 in disease.
|
|
WO/2018/157232A1 |
Compositions comprising modulators of N-terminus activation of the androgen receptor, such as EPI-002 and EPI-506, and a second therapeutic agent are provided. Use of such compositions for treatment of various indications, including pros...
|
|
WO/2018/153279A1 |
The present invention provides novel dihydropyridophthalazinone compounds of Formula (I) as PARP inhibitors, and their pharmaceutically acceptable salts, solvates, hydrates, prodrugs and metabolites thereof, the preparation thereof, and ...
|
|
WO/2018/149991A1 |
The present invention relates to particular sulfonamide derivatives, the pharmaceutically acceptable addition salts thereof, the hydrates thereof and/or the solvates thereof, and also the use thereof as inverse agonists of retinoid-relat...
|
|
WO/2018/146010A1 |
The present invention covers 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamide compounds of general formula (I), in which X, R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds us...
|
|
WO/2018/140512A1 |
Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): (I) or a pharmaceutically acceptable salt, isotopic form, stereoisomer or prodrug thereof, wherein A, B, X,...
|
|
WO/2018/133579A1 |
Provided in the present invention are a ruthenium metal complex of which the molecular formula is L3Ir, applications thereof, and an organic electroluminescent component, where Ir is the center metal atom, L is a ligand, and the structur...
|
|
WO/2018/131690A1 |
[Problem] To provide a novel agrochemical, especially a novel herbicide. [Solution] A ketone or oxime compound represented by formula (1), and a herbicide which contains this compound. (In the formula, B represents B-1 or B-2; Q represen...
|
|
WO/2018/128084A1 |
Provided is a polymerizable compound that has low-wavelength dispersion or reverse-wavelength dispersion, does not readily bubble when made into a coating material, has excellent substrate adhesion when made into a film-like polymer, and...
|
|
WO/2018/115069A1 |
The present invention relates to new compounds of formula (I): showing great affinity and activity towards the subunit α2δ of voltage-gated calcium channels (VGCC),especially the α2δ-1 subunit of voltage-gated calcium channels or dua...
|
|
WO/2018/116107A1 |
Provided are IDO inhibitor compounds of Formula (I) and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and methods for their use in the prevention and/or treatment of diseases ...
|
|
WO/2018/111787A1 |
Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where all substituents are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause...
|
|
WO/2018/106284A1 |
This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or condit...
|
|
WO/2018/093696A1 |
The present invention relates to a compound represented by formula I': and pharmaceutically acceptable salts thereof. The compounds of formula I are inhibitors of diacylglyceride O-acyltransferase 2 ("DGAT2") and may be useful in the tre...
|
|
WO/2018/085813A1 |
Disclosed herein are thieno[2,3-b:5,4-c']dipyridin-8-amine and pyrido[4',3':4,5]thieno[2,3-c]pyridazin-8-amine compounds, which may be useful as positive allosteric modulators of the muscarinic acetylcholine receptor M4 (mAChR M4). Also ...
|
|
WO/2018/082964A1 |
Process for the production of compounds (I). their salts, tautomers, or enantiomers; by reaction of compounds (II) their salts, tautomers, or enantiomers; with compounds (III) their salts, tautomers, or enantiomers. And compounds III in ...
|
|
WO/2018/081377A1 |
The present disclosure is directed to compounds that modulate, e.g., address underlying defects in cellular processing of CFTR (cystic fibrosis transmembrane conductance regulator) activity.
|
|
WO/2018/080216A1 |
The present invention relates to a compound represented by Chemical Formula 1, or a pharmaceutically acceptable salt thereof. The compound according to the present invention can be usefully used for the prevention or treatment of cardiov...
|
|
WO/2018/077875A1 |
The present invention relates to compounds of Formula (I), or an agronomically acceptable salt of said compounds wherein R1a, R1b, R2, X, A, Ra, Rb, Rc, Rd and m are as defined herein. The invention further relates to herbicidal composit...
|
|
WO/2018/081378A1 |
The present disclosure is directed to pyridazinone derivatives of generic formula that modulate, e.g., address underlying defects in cellular processing of CFTR activity.
|
|
WO/2018/068296A1 |
Piperidine compounds of the Formular: (I) and pharmaceutically acceptable salts thereof, wherein X, Y, R 1, R 2, R 3, L, R 4, L 1, Q and R 5 are as defined herein. The compounds and pharmaceutically acceptable compositions comprising a c...
|
|
WO/2018/068282A1 |
Provided are compounds of formula (I),wherein R 1, Y, X 1, X 2, R 2, R 3, R 4, R 5, R 6 and m have any of the values defined in the specification and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment o...
|
|
WO/2018/060575A1 |
The invention relates to compositions comprising 1-chloro-2,2-difluoroethane, and the uses thereof.
|
|
WO/2018/056868A1 |
The invention relates to medicine and more particularly to drugs which act upon the immune system and have immunomodulatory, anti-inflammatory, anti-tumour and anti-oxidant activity, as well as to the chemical pharmaceutical production o...
|
|
WO/2018/051252A2 |
An object of the present invention is to provide an amide compound or a salt thereof that controls a mite. The present invention provides an amide compound represented by Formula (1) : or a salt thereof, wherein R1 represents C1-6 alkyl ...
|
|
WO/2018/045969A1 |
Disclosed is a compound as represented by formula I. The compound is used as an activator for adenosine monophosphate-activated protein kinase to phosphorylate and activate adenosine monophosphate-activated protein kinase, and then to re...
|
|
WO/2018/049271A1 |
Disclosed herein, inter alia, are compounds and methods of use thereof for the modulation of chemokine receptor activity.
|
|
WO/2018/038668A1 |
Compounds of Formula (I): wherein W is NR1A or CR1BR1B; Z is N or CH, R1A is C1-C3alkyl, C1-C3haloalkyl, C3-C4cycloalkyl or phenyl wherein cycloalkyl or phenyl is optionally mono-, di- or tri-substituted with substituents each independen...
|
|
WO/2018/038667A1 |
Compounds of Formula (I): wherein W is NR1A or CR1BR1B; Z is N or CH; R1A is C1-C3alkyl, C1-C3haloalkyl C3-C4cycloalkyl or phenyl wherein cycloalkyl or phenyl is optionally mono-, di- or tri-substituted with substituents each independent...
|
|
WO/2018/015411A1 |
The invention is concerned with the compounds of formula (I): and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I as well a...
|
|
WO/2017/210685A1 |
The present disclosure is directed to pyridazin-3(2H)-one compounds of formula (I), pharmaceutical compositions thereof and methods for modulating or activating a Parkin ligase The present disclosure is also directed to methods of treati...
|
|
WO/2017/202816A1 |
The present invention covers 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamide compounds of general formula (I): in which R1, R2, R3, R4, R5 and R6 are as defined herein, methods of preparing said compounds, intermediate compounds u...
|
|
WO/2017/199028A1 |
A method of preparing an active agent or a salt thereof from a prodrug first compound (1) comprising a propargyl group connected to an oxygen that is directly or indirectly connected to the active agent is provided, wherein the bond betw...
|
|
WO/2017/193034A1 |
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
|
|
WO/2017/193041A1 |
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
|
|
WO/2017/192665A1 |
This disclosure relates to inhibitors of IRES-mediated protein synthesis, compositions comprising therapeutically effective amounts of these compounds, and methods of using those compounds and compositions in treating hyperproliferative ...
|
|
WO/2017/193063A1 |
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
|
|
WO/2017/181918A1 |
The present invention discloses a substituted phthalazone, wherein the substituted phthalazone is a compound represented by formula (I). The invention further discloses a pharmaceutical composition comprising the compound, or a crystalli...
|
|
WO/2017/178582A1 |
The present invention relates to compounds of Formula (I), or an agronomically acceptable salt of said compounds wherein A1, R1, Ra, Rb, Rc and Rd are as defined herein. The invention further relates to herbicidal compositions which comp...
|
|
WO/2017/170759A1 |
Provided is a novel herbicide having a significant herbicidal activity against undesirable plants. A pyridazinone-type compound represented by general formula (I) (wherein X represents -O-, -S-, -SO-, -SO2- or -N(Y)-; Q represents a mono...
|
|
WO/2017/160569A1 |
The present disclosure provides pyrimidine compounds and uses thereof, for example, for the treatment of diseases associated with P2X purinergic receptors. In certain aspects, the present disclosure provides P2X3 and/or P2X2/3 antagonist...
|
|
WO/2017/156181A1 |
The present invention provides compounds, compositions thereof, and methods of using the same.
|
|
WO/2017/153958A1 |
The present invention provides crystalline Form M of Olaparib, amorphous form of Olaparib, process for their preparation, pharmaceutical composition thereof and their use as medicaments.
|
|
WO/2017/156179A1 |
The present invention provides compounds, compositions thereof, and methods of using the same.
|
|
WO/2017/156165A1 |
The present invention provides compounds, compositions thereof, and methods of using the same.
|
|
WO/2017/156177A1 |
The present invention provides compounds, compositions thereof, and methods of using the same.
|
|
WO/2017/153518A1 |
A compound of formula (Ia), (Ib) or (Ic) wherein: n is 1 or 2; RN is H or Me; R1 is optionally one or more halo or methyl groups; R2a and R2b are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2O...
|
|
WO/2017/150654A1 |
The present invention provides an agent for treating malignant tumor, comprising a compound of formula (1): wherein R1 to R4 are hydrogen atom, halogen, or etc., Y is optionally-substituted alkylene group or etc.
|
|
WO/2017/147701A1 |
The present application is directed to compounds of Formula I: (I) compositions comprising these compounds and their uses, for example as medicaments for the treatment of diseases, disorders or conditions mediated or treatable by inhibit...
|
